These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22160088)

  • 1. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.
    Gore SD
    Hematology Am Soc Hematol Educ Program; 2011; 2011():550-5. PubMed ID: 22160088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Griffiths EA; Gore SD
    Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
    Tohyama K
    Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
    Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
    J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Gore SD
    J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP
    J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

  • 10. [Application of DNA methyltransferase inhibitors for myelodysplastic syndrome].
    Lü XY; Du YX; Dai ZH; Liu M; Liu XY; Zhang KL
    Yi Chuan; 2013 Feb; 35(2):136-40. PubMed ID: 23448925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methyltransferase inhibitors in myelodysplastic syndrome.
    Silverman LR
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):585-94. PubMed ID: 15494296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
    Sekeres MA
    Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
    Ørskov AD; Grønbæk K
    Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
    Gore SD
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.